KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) FCF Margin (2016 - 2025)

Travere Therapeutics' FCF Margin history spans 13 years, with the latest figure at 46.79% for Q4 2025.

  • For Q4 2025, FCF Margin rose 9455.0% year-over-year to 46.79%; the TTM value through Dec 2025 reached 10.29%, up 11217.0%, while the annual FY2025 figure was 7.7%, 10954.0% up from the prior year.
  • FCF Margin reached 46.79% in Q4 2025 per TVTX's latest filing, up from 35.44% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 57.66% in Q3 2021 to a low of 327.8% in Q3 2022.
  • Average FCF Margin over 5 years is 121.28%, with a median of 68.24% recorded in 2024.
  • Peak YoY movement for FCF Margin: crashed -38546bps in 2022, then soared 26579bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 57.66% in 2021, then plummeted by -554bps to 261.54% in 2022, then rose by 2bps to 257.07% in 2023, then skyrocketed by 81bps to 47.76% in 2024, then surged by 198bps to 46.79% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's FCF Margin are 46.79% (Q4 2025), 35.44% (Q3 2025), and 4.35% (Q2 2025).